Research programme - cancer therapeutics - Artios Pharma

Drug Profile

Research programme - cancer therapeutics - Artios Pharma

Alternative Names: DDR - cancer therapeutics - Artios Pharma; Pol-theta

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research Technology
  • Developer Artios Pharma; Masaryk University
  • Class Antineoplastics
  • Mechanism of Action DNA repair enzyme modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Jun 2017 Early research in Cancer in Czech Republic (Parenteral)
  • 12 Jun 2017 Artios Pharma and Masaryk University agree to develop cancer therapeutics in Czech Republic for Cancer
  • 21 Sep 2016 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top